Actively Recruiting
Biology of Cerebral Arteriovenous Malformations: Link Between Blood Biomarkers and Hemorrhagic Prognosis
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2025-06-25
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Cerebral arteriovenous malformations (AVMs) are tangled abnormal blood vessels called nidus that directly connect arteries to veins, bypassing normal circulation. These malformations are a significant cause of hemorrhagic stroke. Researchers are studying whether bleeding from cerebral AVMs is linked to small vessels near the nidus, possibly involving white blood cells and platelet-related microvascular issues. This observational study examines the relationship between blood biomarkers and the risk of bleeding in cerebral AVMs. Participants include patients with cerebral AVMs who are undergoing treatment such as surgery or endovascular methods, or who are being clinically monitored without intervention. The study measures markers related to blood vessel lining, platelets, neutrophils, and new blood vessel growth at six months to understand their connection to bleeding risk. Participants will provide blood samples that researchers analyze for specific biomarkers related to AVM prognosis. The main outcomes focus on associations between these blood markers and bleeding risk over six months. The study involves monitoring health status and collecting data without administering treatments, with participation length depending on individual follow-up schedules.
CONDITIONS
Brief Title
Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Diagnosed with cerebral arteriovenous malformation (AVM)
- Undergoing intervention (endovascular treatment or surgery) or clinical monitoring only
- Able to provide express consent to participate
- For children: informed consent from both parents or one when the other cannot consent in time as per study requirements
You will not qualify if you...
- Patient under a legal protection measure
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants who undergo routine care are observed to assess biological markers and prognosis over time.
Visits scheduled according to clinical monitoring or intervention plan
Trial Site Locations
Total: 1 location
1
Fondation Ophtalmologique Rotschild
Paris, France, 75019
Actively Recruiting
Research Team
A
Amélie Yavchitz
J
Jean Philippe DESILLES
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here